Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Taylor, P, Takeuchi, T, Burmester, G, Durez, P, Smolen, J, Deberdt, W, Zhong, J, Teres, JR, Bello, N, Winthrop, K, Pope, J
Формат:	Conference item
Хэл сонгох:	English
Хэвлэсэн:	Journal of Rheumatology 2022

Ижил төстэй зүйлс

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
-н: Taylor, P, зэрэг
Хэвлэсэн: (2021)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
-н: Weinblatt, M, зэрэг
Хэвлэсэн: (2017)

Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
-н: Weinblatt, M, зэрэг
Хэвлэсэн: (2018)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
-н: Gerd Burmester, зэрэг
Хэвлэсэн: (2020-02-01)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
-н: Naoki Iwamoto, зэрэг
Хэвлэсэн: (2021-07-01)

Baricitinib for the treatment of rheumatoid arthritis
-н: Ivan Urits, зэрэг
Хэвлэсэн: (2020-12-01)

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2018)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
-н: Keystone, E, зэрэг
Хэвлэсэн: (2015)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
-н: Paul Emery, зэрэг
Хэвлэсэн: (2021-01-01)

Baricitinib exposure during pregnancy in rheumatoid arthritis
-н: Giulia Costanzo, зэрэг
Хэвлэсэн: (2020-01-01)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
-н: Smolen, JS, зэрэг
Хэвлэсэн: (2020)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study
-н: Smolen, JS, зэрэг
Хэвлэсэн: (2020)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
-н: Keystone, EC, зэрэг
Хэвлэсэн: (2017)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
-н: Emery, P, зэрэг
Хэвлэсэн: (2019)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
-н: Taylor, PC, зэрэг
Хэвлэсэн: (2023)

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care
-н: Moeller, B, зэрэг
Хэвлэсэн: (2019)

A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19
-н: Bieber, T, зэрэг
Хэвлэсэн: (2022)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
-н: Paul Emery, зэрэг
Хэвлэсэн: (2020-05-01)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
-н: Weinblatt, M, зэрэг
Хэвлэсэн: (2018)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
-н: Taylor, P, зэрэг
Хэвлэсэн: (2022)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
-н: Kawalec P, зэрэг
Хэвлэсэн: (2019-02-01)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
-н: Yue Yang, зэрэг
Хэвлэсэн: (2020-09-01)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
-н: Rosemary Akinbisehin, зэрэг
Хэвлэсэн: (2024-06-01)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
-н: Paul Emery, зэрэг
Хэвлэсэн: (2020-07-01)

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
-н: Fautrel, B, зэрэг
Хэвлэсэн: (2019)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
-н: Chan-yuan Wu, зэрэг
Хэвлэсэн: (2023-09-01)

Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study
-н: Akira Maeyama, зэрэг
Хэвлэсэн: (2024-12-01)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
-н: Strand, V, зэрэг
Хэвлэсэн: (2021)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
-н: A. E. Karateev
Хэвлэсэн: (2020-09-01)

Baricitinib: key results of long-term use in rheumatoid arthritis
-н: N. V. Chichasova, зэрэг
Хэвлэсэн: (2024-08-01)

Efficacy of baricitinib combined with iguratimod in the treatment of refractory rheumatoid arthritis
-н: CHEN Jianming, LEI Meihong, ZHANG Lanxia
Хэвлэсэн: (2023-11-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
-н: Cristina Martinez-Molina, зэрэг
Хэвлэсэн: (2024-02-01)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
-н: Tanaka, Y, зэрэг
Хэвлэсэн: (2018)